tetano
Editor, Senior Moderator
Cureus
. 2021 Sep 9;13(9):e17845.
doi: 10.7759/cureus.17845. eCollection 2021 Sep.
Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
Lucca Pizzato Tondo[SUP] 1 [/SUP], Eduardo Beck Paglioli Neto[SUP] 1 [/SUP], Soel Arpini[SUP] 1 [/SUP], Giordani Passos[SUP] 1 [/SUP], Jefferson Becker[SUP] 1 [/SUP]
Affiliations
Abstract
Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described that encephalitis due to COVID-19 may be caused by the proinflammatory state due to the cytokine storm or direct invasion of the virus in the CNS. Here we present a case of a 66-year-old man with bipolar disorder and moderate respiratory COVID-19 symptoms who presented to the emergency department with a decreased level of consciousness. Brain computerized tomography (CT) showed no acute pathology. A thorough investigation of other possible causes of CNS affection was negative. The patient was treated with pulse therapy with methylprednisolone and presented a significant improvement of his neurological condition, being discharged with a complete neurological recovery five days after the start of the treatment. This case illustrates the importance of a high index of suspicion in diagnosing severe CNS impairment in mild respiratory COVID-19 cases. Also, this case corroborates with previous reports of glucocorticoid response in CNS impairment associated with COVID-19, although more robust studies are required to confirm this relation.
Keywords: corticoid; covid 19 encephalitis; covid-19; covid-19 treatment; encephalitis; encephalitis treatment; mild to moderate covid-19.
. 2021 Sep 9;13(9):e17845.
doi: 10.7759/cureus.17845. eCollection 2021 Sep.
Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
Lucca Pizzato Tondo[SUP] 1 [/SUP], Eduardo Beck Paglioli Neto[SUP] 1 [/SUP], Soel Arpini[SUP] 1 [/SUP], Giordani Passos[SUP] 1 [/SUP], Jefferson Becker[SUP] 1 [/SUP]
Affiliations
- PMID: 34660051
- PMCID: PMC8501896
- DOI: 10.7759/cureus.17845
Abstract
Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described that encephalitis due to COVID-19 may be caused by the proinflammatory state due to the cytokine storm or direct invasion of the virus in the CNS. Here we present a case of a 66-year-old man with bipolar disorder and moderate respiratory COVID-19 symptoms who presented to the emergency department with a decreased level of consciousness. Brain computerized tomography (CT) showed no acute pathology. A thorough investigation of other possible causes of CNS affection was negative. The patient was treated with pulse therapy with methylprednisolone and presented a significant improvement of his neurological condition, being discharged with a complete neurological recovery five days after the start of the treatment. This case illustrates the importance of a high index of suspicion in diagnosing severe CNS impairment in mild respiratory COVID-19 cases. Also, this case corroborates with previous reports of glucocorticoid response in CNS impairment associated with COVID-19, although more robust studies are required to confirm this relation.
Keywords: corticoid; covid 19 encephalitis; covid-19; covid-19 treatment; encephalitis; encephalitis treatment; mild to moderate covid-19.